Biomarker Identification and Nutritional Intervention of Primary Sarcopenia Based on Gut-muscle Axis - Trial NCT06347835
Access comprehensive clinical trial information for NCT06347835 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Not yet recruiting. The study focuses on Sarcopenia. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
N/A
Apr 01, 2024
Jan 01, 2026
Primary Outcome
Change from Baseline of Appendicular skeletal muscle mass index at 12 weeks,Change from Baseline of grip strength at 12 weeks
Summary
The loss of skeletal muscle mass and function usually occurs with aging, known as primary
 sarcopenia. Sarcopenia has a prevalence of 11.6% among the elderly population in China and is
 closely associated with increased risks of falls, disability, and mortality. Currently, there
 is a lack of definition criteria for sarcopenia based on biomarkers. The Gut-Muscle Axis
 hypothesis suggests a complex interplay between gut microbiota and skeletal muscle.
 Nutritional intervention targeting the gut microbiota potentially plays a significant role in
 muscle regeneration. Therefore, this study aims to explore the effects of symbiotic and whey
 protein on muscle, gut microbiota, and clinical outcomes among sarcopenia patients, to
 provide a reference for further diagnosis and treatment of sarcopenia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06347835
Non-Device Trial